Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LySATRA: SBRT Combined With ATRA in Oligo-metastatic Solid Cancer
NCT06439888Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Jul 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tretinoin in solid tumor (3 arms), sponsored by Gustave Roussy. Primary endpoints: Dose-limiting toxicities at 3 weeks and Lympho-protective efficacy. Started Jul 2024; status: recruiting.
02
Drugs
tretinoin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06439888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439888.